Piramal Pharma Limited Announces Q1FY26 Results
Piramal Pharma Limited (NSE: PPLPHARMA, BSE: 543635), a prominent global pharmaceutical company, has revealed its standalone and consolidated financial results for the first quarter (Q1) ending this June. With a focus on solid growth in various sectors, the company continues to adapt to market challenges while positioning itself for future success.
Financial Highlights
The consolidated financial presentation included notable metrics. Revenue from operations for Q1FY26 stood at ? 1,934 crores, showing a marginal decrease from ? 1,951 crores in Q1FY25. However, excluding the effects of destocking in a major Contract Development and Manufacturing Organization (CDMO) product, the year-on-year revenue growth was noted to be in the early double digits.
Consolidated Financial Overview
This quarter’s EBITDA margin illustrated a decrease to 9%, down from 11% reported in the same quarter last year. This decrease was influenced by inventory destocking; however, the profitability of overseas facilities within the CDMO segment saw improvements.
Key Performance Indicators
For Q1FY26, the company reported:
- Significant insights include a Net-Debt to EBITDA ratio of 2.6x.
- The best-in-class quality record remains intact with no observations reported from the recent USFDA inspections at its Aurora facility.
- Piramal was assigned an ESG rating of '61' for FY2024 by NSE Sustainability Ratings, reflecting its dedication to sustainability.
Chairperson’s Insights
Nandini Piramal, Chairperson of Piramal Pharma Limited, expressed optimism regarding the firm’s performance. She noted, "Excluding the impact of destocking in a large on-patent product, our CDMO business exhibited mid-teen revenue growth. The CHG sector is anticipated to show significant growth for the remainder of the fiscal year."
Business Strategies and Developments
Piramal Pharma continues to focus on growth through a diversified approach. The CDMO segment specifically demonstrated mid-teen growth, primarily fueled by enhanced profitability from international facilities.
Operational Highlights
The company has broken ground for an expansion project in the US aimed at sterile injectable drug products, which will accelerate their integrated ADC development and manufacturing process. Piramal's commitment to innovation and excellence is further reflected in its successful USFDA inspection results.
Piramal Consumer Healthcare Performance
In the consumer healthcare segment, revenue growth of 18% was recorded within its Power Brands. This notable performance was driven by products like Little's and CIR, alongside a strong e-commerce presence that accounted for 23% of total sales.
Future Outlook
Despite near-term challenges, Piramal Pharma remains focused on its long-term goal of reaching $2 billion in revenue by FY2030 with a 25% EBITDA margin.
Frequently Asked Questions
What were the total revenues for Q1FY26?
The total revenue from operations for Q1FY26 was ? 1,934 crores.
How did the EBITDA margin change from the previous year?
The EBITDA margin fell to 9% in Q1FY26 from 11% in Q1FY25.
What are the expectations for the CHG business moving forward?
The CHG business is anticipated to grow significantly in the following quarters, benefiting from improved order timing.
How is Piramal Pharma addressing sustainability?
Piramal has been awarded an ESG rating of '61' for FY2024, showcasing its commitment to sustainable practices.
When will the earnings conference call take place?
The earnings conference call is scheduled for July 29, 2025, at 9:30 AM IST.
